Review article on potential epigenetic compounds that could be utilized to prevent or treat atherosclerosis.
In a collaborative effort between the groups of Vascular Medicine and Medical Biochemistry of the Academic Medical Center (Prof. Erik Stroes, Prof. de Winther) a review article has been published in the esteemed Athersclerosis journal (Oct, 2018).
In this review, potential epigenetic compounds are studied that could be utilized to prevent or treat atherosclerosis based on the epigenetic concept.
The pivotal role of epigenetic changes in the control of gene expression has been profiled in several diseases, such as cancer and inflammatory disorders. In the last decade, increasing evidence has also linked aberrant epigenetic modulation as a contributor to cardiovascular disease development. Differential profiles of DNA methylation, histone methylation and acetylation have consistently been observed in tissues and cells (comprising the aortic lesions, vascular endothelium and monocytes) from patients with cardiovascular disease. This highlights the therapeutic potential of epigenetic drugs for cardiovascular treatment.
The full review article can be found here or https://doi.org/10.1016/j.atherosclerosis.2018.10.006